Advanced Filters
noise

A, Almada N Clinical Trials

A listing of A, Almada N clinical trials actively recruiting patients volunteers.

Found 10,697 clinical trials
L Liu

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Fenofibrate in Combination with Ursodeoxycholic Acid in Subjects with Primary Biliary Cholangitis (PBC)

18 - 75 years of age All Phase 3
N Nancy Kuntz, MD

A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC

This study will measure how adults with CIDP receiving IVIg treatment adjust to efgartigimod PH20 SC. The study duration for each participant will be approximately 17 to 19 weeks.

18 years of age All Phase 4

A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis

The primary objective of the study is to evaluate the long-term safety, tolerability, and efficacy of TLL-018 in patients with rheumatoid arthritis (RA) who have completed a preceding randomized controlled trial with TLL-018.

18 - 75 years of age All Phase 3

A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)

This is a phase II single-arm open-label study to investigate the efficacy and safety of volrustomig in women with FIGO 2018 stage IIIA to IVA cervical cancer who have not progressed following platinum-based concurrent chemoradiation therapy (CCRT).

18 years of age Female Phase 2

A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections …

18 - 45 years of age All Phase 1
U US GSK Clinical Trials Call Center

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

The primary objective of the study is to investigate the safety and tolerability of ascending doses of GSK3862995B following single dose in healthy participants and repeat doses in participants with Chronic obstructive pulmonary disease (COPD).

18 - 75 years of age All Phase 1
Y Yan Deng

Adjunctive Treatment With L-methylfolate for Treatment-Resistant Generalized Anxiety Disorder: a Pilot Study

The goal of this feasibility study is to determine the tolerability and safety of add on treatment with L-methylfolate in patients with treatment-resistant generalized anxiety disorder (GAD). The primary objective is to monitor for side effects and other risks associated with the treatment. Secondary objectives are to compare the severity …

18 - 65 years of age All Phase 4

A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid Arthritis

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis with inadequate response to a least one biologic disease-modifying antirheumatic drug (bDMARD)or targeted synthetic disease-modifying antirheumatic drug (tsDMARD). Study participation is approximately 50 weeks, including a 6-week …

18 - 75 years of age All Phase 2
M Mariam Samara

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of recombinant human heparan N-sulfatase (rhHNS, GC1130A) administered via intracerebroventricular access device in patients with Sanfilippo Syndrome Type A (MPS IIIA).

12 - 18 years of age All Phase 1
P Paul Graham, M D

A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy

To compare same-day discharge and overnight (or longer) observation practices and learn more about the differences in patient preferences, safety outcomes, and economic and resource impact

18 years of age All Phase 2

Simplify language using AI